Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
2015 · The Lancet Oncology · 1,089 citations
https://doi.org/10.1016/s1470-2045(15)00188-6